Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 2
2009 1
2010 1
2011 2
2013 1
2014 2
2016 2
2017 1
2018 3
2019 1
2020 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean avlasta (2 results)?
Zoledronic Acid (Reclast(), Aclasta()): A Review in Osteoporosis.
Dhillon S. Dhillon S. Drugs. 2016 Nov;76(17):1683-1697. doi: 10.1007/s40265-016-0662-4. Drugs. 2016. PMID: 27864686 Review.
Zoledronic acid (Reclast(), Aclasta()) is an intravenous, highly potent aminobisphosphonate approved worldwide, including in the USA, EU and Japan for use in patients with primary or secondary osteoporosis or low bone mass (approved indications vary between countries). ...
Zoledronic acid (Reclast(), Aclasta()) is an intravenous, highly potent aminobisphosphonate approved worldwide, including in the USA, …
Efficacy of Yigu versus Aclasta in Chinese postmenopausal women with osteoporosis: a multicenter prospective study.
Li M, Cheng Q, Huo YN, Chao AJ, He L, Xue QY, Xu J, Yan SG, Jin H, Zhang ZL, Lin JH, Jin XL, Xu YJ, Liu F, Xia WB. Li M, et al. Arch Osteoporos. 2022 Jan 12;17(1):14. doi: 10.1007/s11657-021-01052-y. Arch Osteoporos. 2022. PMID: 35020038 Free PMC article. Clinical Trial.
INTRODUCTION: Yigu has been approved its bioequivalence to Aclasta. However, the clinical efficacy and safety of Yigu have not been evaluated yet. ...RESULTS: A total of 458 postmenopausal women with osteoporosis were enrolled (n = 227, Yigu; n = 231, Aclasta). The …
INTRODUCTION: Yigu has been approved its bioequivalence to Aclasta. However, the clinical efficacy and safety of Yigu have not been e …
Zoledronic Acid.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000681 Free Books & Documents. Review.
[Zoledronate-induced panuveitis].
Bergua A, Hohberger B. Bergua A, et al. Ophthalmologe. 2018 Jul;115(7):592-594. doi: 10.1007/s00347-017-0538-3. Ophthalmologe. 2018. PMID: 28748264 German.
Zoledronate-induced (Aclasta) uveitis is a rare iatrogen-induced inflammation of ocular structures, which can result in substantial morphological and functional limitations. ...
Zoledronate-induced (Aclasta) uveitis is a rare iatrogen-induced inflammation of ocular structures, which can result in substantial m …
Drugs for postmenopausal osteoporosis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Jul 13;62(1602):105-112. Med Lett Drugs Ther. 2020. PMID: 32728009 Corrected and republished. Review. No abstract available.
Role of zoledronic acid in the prevention and treatment of osteoporosis.
Räkel A, Boucher A, Ste-Marie LG. Räkel A, et al. Clin Interv Aging. 2011;6:89-99. doi: 10.2147/CIA.S7282. Epub 2011 Mar 28. Clin Interv Aging. 2011. PMID: 21594000 Free PMC article. Review.
Taken once a year, intravenous zoledronic acid (Zol) (Reclast or Aclasta) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma h …
Taken once a year, intravenous zoledronic acid (Zol) (Reclast or Aclasta) is a third-generation nitrogen-containing bisphosphonate th …
Annual zoledronic acid for osteoporosis.
BMJ Group. BMJ Group. Drug Ther Bull. 2008 Dec;46(12):93-6. Drug Ther Bull. 2008. PMID: 19056701 Review.
Zoledronic acid (Aclasta - Novartis) is the first bisphosphonate to be licensed in the UK as a once-yearly intravenous treatment for women with postmenopausal osteoporosis. ...
Zoledronic acid (Aclasta - Novartis) is the first bisphosphonate to be licensed in the UK as a once-yearly intravenous treatment for …
Zoledronic acid: a review of its use in the treatment of osteoporosis.
Deeks ED, Perry CM. Deeks ED, et al. Drugs Aging. 2008;25(11):963-86. doi: 10.2165/0002512-200825110-00007. Drugs Aging. 2008. PMID: 18947264 Review.
Zoledronic acid (Aclasta; Reclast), a third-generation nitrogen-containing bisphosphonate, is the first once-yearly treatment to have been approved for use in patients with postmenopausal osteoporosis or at high risk of fracture. ...
Zoledronic acid (Aclasta; Reclast), a third-generation nitrogen-containing bisphosphonate, is the first once-yearly treatment to have …
22 results